21 February 2024
21 February 2024
Xolair is the first FDA-approved drug to reduce allergic reactions in people with one or more food allergies, as per Roche’s announcement.
TECVAYLI is a subcutaneous bispecific antibody that acts on both BCMA on multiple myeloma cells and CD3 on T-cells.
Priority review acceptance is based on positive results from the pivotal Phase III study of Keytruda/chemotherapy in endometrial cancer.
China-based Everest will pay $4m upon termination of its partnership agreement with Canada-based Providence.
The filing is based on data from the Phase I/II KRYSTAL-1 study that assessed the efficacy and safety of KRAZATI.
Following FDA orphan designation in 2023, the company is eligible for market exclusivity in mesothelioma for both regions.
Genezen's clients can gain immediate access to the technology for stable and scalable high-titer clinical lentivirus production.
Amtagvi is an Iovance T-cell therapy for advanced melanoma.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
